Vir Biotechnology Inc
Cerrado
SectorSanidad
10.57 0.09
Resumen
Variación precio
24h
Mínimo
10.37
Máximo
10.92
Ingresos | 80M -46M |
|---|---|
Ventas | 239M 239M |
BPA | 0.47 |
Margen de beneficios | -19.09 |
Empleados | 367 |
EBITDA | 201M 78M |
Próximas Ganancias | 4 nov 2026 |
|---|
Capitalización Mercado | 426M 1.9B |
|---|---|
Apertura anterior | 10.48 |
Cierre anterior | 10.57 |
Noticias sobre sentimiento de mercado
By Acuity
25%
75%
55 / 339 Clasificación en Healthcare
Vir Biotechnology Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Vir Biotechnology Inc previsión
Sentimiento
By Acuity
55 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.